Companies announce stock splits all the time, and so far this year a number of high profile companies have divvied up their ...

These are the 300 companies whose success goes beyond profits to include employee and customer sentiment, cybersecurity, ...

Vertex's diverse pipeline, including Casgevy for SCD, suzetrigine for chronic pain, and the vanzacaftor triple for CF, positions it for growth despite launch challenges. Casgevy's complex ...

Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals (NASDAQ:VRTX). And retail traders should know. We noticed this today when the trades showed up on ...

Vertex Pharmaceuticals Background Information (This description is provided by the company.) Vertex is a global biotechnology company that invests in scientific innovation to create transformative ...

Vertex Pharmaceuticals Inc. ( (VRTX)) has released its Q3 earnings. Here is a breakdown of the information Vertex Pharmaceuticals Inc. presented to its investors. Vertex Pharmaceuticals Inc., a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) have appreciated more than 40% since I shifted my coverage to hold/neutral last year, and I am not surprised since the company executed ...

Vertex Pharmaceuticals (VRTX) closed the latest trading day at $484.94, indicating a +0.67% change from the previous session's end. This move lagged the S&P 500's daily gain of 0.77%. On the other ...

Nov 4 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab raised its annual revenue forecast on Monday after it beat third-quarter estimates on demand for its cystic fibrosis (CF ...

In the latest market close, Vertex Pharmaceuticals (VRTX) reached $475.08, with a +1% movement compared to the previous day. The stock exceeded the S&P 500, which registered a loss of 0.33% for ...